FDA OKs Two Tafamidis Formulations for Rare Cardiomyopathy

These are the first FDA-approved treatments for transthyretin-mediated amyloidosis cardiomyopathy, a rare and often fatal disease caused by deposition of amyloid fibrils in the myocardium.
FDA Approvals …read more